Home Merck Announces Second-Quarter 2014 Financial Results
 

Keywords :   


Merck Announces Second-Quarter 2014 Financial Results

2014-07-29 12:56:00| Merck.com - Corporate News

Dateline City: WHITEHOUSE STATION, N.J. Second-Quarter 2014 Non-GAAP EPS of $0.85, Excluding Certain Items, and GAAP EPS of $0.68 2014 Full-Year Non-GAAP EPS Target of $3.43 to $3.53, Excluding Potential Venezuelan Bolivar Devaluation and Certain Other Items; 2014 Full-Year GAAP EPS Target of $4.44 to $4.77 2014 Full-Year Non-GAAP EPS Target Includes $0.06 to $0.09 Anticipated Dilution From Planned Sale of Merck Consumer Care and Research Collaboration With Bayer, and Planned Acquisition of Idenix Generated Worldwide Sales of $10.9 Billion, a Decrease of 1 Percent, Reflecting Unfavorable Impact of Patent Expiries, Divested Products and Decline in Sales of Hepatitis C Products Grew Top Five Franchises by 6 Percent in Total Pembrolizumab (MK-3475), an Investigational Anti-PD-1 Antibody, Accepted in Second Quarter for Regulatory Review in Both the United States and European Union WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2014. Language: English Contact: MerckMedia:Steve Cragle, 908-423-3461Lainie Keller, 908-423-4187orInvestors:Joe Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: results financial announces merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Public Advisory Number 4A
18.06Summary for Potential Tropical Cyclone One (AT1/AL012024)
18.06Atlantic Tropical Weather Outlook
18.06Eastern North Pacific Tropical Weather Outlook
18.06CCAI Recognizes 2024 Award Recipients
18.06German court dismisses anti-competitive claims against Tageos
18.06A Request From the A League of Their Own Womens Special Interest Group
More »